According to a recently published study by Future Market Insights, the global hyperammonemia treatment market size is expected to reach a valuation of US$ 1,318.05 Million in 2023 and is projected to reach US$ 2,100 Million by 2033, trailing a CAGR of 4.77%.
The rising prevalence of urea cycle disorders and extensive research and development are the primary factors driving the growth of Hyperammonemia treatment market. Growing expansion of infrastructure development, and support from governments are anticipated to influence the market demand. The increasing awareness among masses and growing number of innovative diagnostic approaches are increasing the growth of Hyperammonemia treatment market.
๐ฎ๐๐ ๐ณ๐๐๐๐๐ ๐บ๐๐๐๐๐ ๐ช๐๐๐@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16383
Additionally, research and development studies highlighting the genetic characterization of Hyperammonemia will help market players align their product development, which will contribute in market expansion. However,ย complications of long-term therapy, production of these drugs, and challenges in diagnosing are likely to restrict growth of global Hyperammonemia treatment market.
Key Takeaways from the Market Study
- Global hyperammonemia treatment market is expected to grow 1.6x from 2023 to 2033
- US is estimated to lead the market in North America while recording a market share of 48%.
- South Asia is expected to register a 4.2% CAGR with regard to hyperammonemia treatment disbursement
- By treatment type, glycerol phenylbutyrate is estimated to account for a segment share of 35.5% by end of 2033.
- By distribution channel, hospital pharmacies will contribute with a segment share of around 48% by end of the forecast period.
- Developments in gene therapy for the treatment of Hyperammonemia are expected to proliferate product demand.
โAdvancements in gene therapy and growing investments in Research & development for treatment of hyperammonemia will bolster product demandโ, comments an FMI analyst
๐จ๐๐ ๐จ๐ ๐จ๐๐๐๐๐๐@ https://www.futuremarketinsights.com/ask-question/rep-gb-16383
Competitive Landscape
The market is fragmented and moderately competitive. The strategies such as mergers and acquisitions adopted by major market players will boost the studied market growth. The major players in the market are: Bausch Health Companies, Inc., Recordati Rare Diseases Inc., Lucane Pharma SA, Acer Therapeutics, Ultragenyx Pharmaceutical Inc, Aeglea BioTherapeutics, Arcturus Therapeutics Holdings Inc., Orpharma Pty Ltd, Abbott Laboratories, and Selecta Biosciences, Inc. Some recent developments in this industry are as follows:
- In January 2021, Acer Therapeutics and Relief Therapeutics Holding AG, a biopharmaceutical company, entered into collaboration and license agreement for the worldwide development and commercialization of acer-001, a sodium Phenylbutyrate drug conjugate for the treatment of urea cycle disorders.
- In July 2022, Versantis AG revealed that the U.S. Food and Drug Administration (FDA) designated its major product candidate VS-01, an ammonia clearance enhancer, a rare pediatric disease designation for the treatment of urea cycle disorders.
- In October 2021, According to Acer Therapeutics Inc. and its collaboration partner, RELIEF THERAPEUTICS (UCDs). The U.S. Food and Drug Administration (FDA) accepted the submission of the New Drug Application (NDA) for the drug ACER-001 (sodium phenylbutyrate) for the treatment of patients with urea cycle disorders.
- In January 2021, Recordati Rare Diseases Inc. received the U.S. Food and Drug Administration (FDA) approval for CARBAGLU for the treatment of acute hyperammonemia
More Valuable Insights Available
Future Market Insights offers an unbiased analysis of the global hyperammonemia treatment market, providing historical data for 2018-2022 and forecast statistics from 2023-2033.
To understand opportunities in the Hyperammonemia treatment market, the market is segmented on the basis of treatment type (amino acid supplements, sodium phenylbutyrate, glycerol phenylbutyrate, sodium benzoate and others), route of administration (oral and injectable) and distribution channel (hospital pharmacies, online pharmacies and retail pharmacies) across seven major regions (North America, Latin America, Europe, South Asia, East Asia, Oceania and Middle East & Africa)
About the Healthcare Division at Future Market Insights
The healthcare team at Future Market Insights offers expert analysis, time efficient research, and strategic recommendations with an objective to provide authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 million+ data points, the team has been analyzing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis on key trends including competitive landscape, profit margin, and research development efforts.
๐ฉ๐๐ ๐ต๐๐/๐ท๐๐๐๐๐๐๐@ https://www.futuremarketinsights.com/checkout/16383
Key Segments Profiled in the Hyperammonemia Treatment Market Industry Survey
By Treatment Type:
- Amino Acid Supplements
- Sodium Phenylbutyrate
- Glycerol Phenylbutyrate
- Sodium Benzoate
- Others
By Route of Administration:
- Oral
- Injectable
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
About FMI:
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries:ย sales@futuremarketinsights.com
Browse All Reports :ย https://www.futuremarketinsights.com/reports
LinkedIn|ย Twitter|ย Blogs